Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00055_DB08813_nanopub.RAlYC0dLFL2Nm0jMvF5rYaf-wnVUu2_vfnz4DIUSMpzh0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00055_DB08813 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00055_DB08813 label "DDI between Drotrecogin alfa and Nadroparin - The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of low molecular weight heparins such as nadroparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin. [drugbank_resource:DB00055_DB08813]" assertion.
- drugbank_resource:DB00055_DB08813 identifier "drugbank_resource:DB00055_DB08813" assertion.
- drugbank_resource:DB00055_DB08813 title "DDI between Drotrecogin alfa and Nadroparin - The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of low molecular weight heparins such as nadroparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin." assertion.
- drugbank:DB00055 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00055_DB08813 assertion.
- drugbank:DB08813 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00055_DB08813 assertion.